Fig. 2From: Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entryVisualization of the predicted interactions between atorvastatin, raloxifene and trifluoperazine, and the SARS-CoV-2 Mpro (left panel) and RdRp (right panel)Back to article page